MedTrace Logo

Efficacy Study of Memantine Hydrochloride and Escitalopram for the Treatment of Co-Morbid Depression and Alcoholism.

NCT00368862 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2006-08-29

No results posted yet for this study

Summary

The aim of the present study was to examine the influence of memantine, a noncompetitive NMDA receptor blocker, in depression co-morbid with long term alcohol heavy use comparing to SSRI-inhibitor, escitalopram. Second goal is to compare their influence to cognitive tasks and the third goal is to follow up alcohol-use with these two medicines.

Conditions

Interventions

DRUG

Ebixa (memantine hydrochloride)

DRUG

Cipralex (escitalopram)

Sponsors & Collaborators

  • Finnish Foundation for Alcohol Studies

    collaborator OTHER

  • Finnish Institute for Health and Welfare

    lead OTHER_GOV

Principal Investigators

  • Hannu E Alho, MD, PhD · National Public Health Institute, Department of Mental health and Alcohol Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-12-31
Completion
2006-06-30

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00368862 on ClinicalTrials.gov